ArticleLipids in health and disease2026
Cascade screening and genetic variant pathogenicity assessment for familial hypercholesterolemia in a township‑based elderly population.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFamilial hypercholesterolemia (FH) is a common, autosomal semi-dominant inherited disorder causing premature cardiovascular disease. However, it remains underdiagnosed, especially in community settings. Early diagnosis, particularly in children, is critical for timely intervention. Furthermore, the pathogenicity of genetic variants of uncertain significance poses a major challenge for clinical interpretation.
methodsWe conducted a systematic screening program in a town in Wujiang District, Suzhou, China. Eligible individuals (based on LDL-C ≥ 3.8 mmol/L, family history, or voluntary participation) underwent genetic testing for FH-related genes (LDLR, PCSK9, APOB and LDLRAP1) and pharmacogenetic variants (SLCO1B1 and APOE). Cascade screening was offered to relatives of probands with putative pathogenic variants. Identified variants were functionally characterized through in vitro assays, including intracellular expression, PCSK9 secretion, LDLR degradation and LDL uptake assays.
resultsAmong 27 eligible participants, 13 (48.1%) carried putative pathogenic variants, with the majority (11/13) in LDLR. Cascade screening of eight families identified 13 additional carriers, with no pediatric carriers detected. Functional assays demonstrated that LDLR c.190delT and c.1448G > A resulted in complete loss of function, while c.1879G > A impaired protein maturation and reduced function to approximately 50% of wild-type. Other missense variants exhibited partial loss of function. For PCSK9, the c.658G > A variant was experimentally confirmed as a gain-of-function variant through in vitro studies.
conclusionsThis study establishes a comprehensive FH diagnostic model from community screening to functional validation. Our findings confirm a high FH prevalence in this Chinese cohort and underscore the indispensable role of functional assays and pharmacogenetics in enabling precise diagnosis and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.